{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Myeloma: How to Fit the Three New Drugs into Clinical Practice ((Non-Physician Credit))

Activity Steps

Description

The certificate for this activity is for NON-PHYSICIANS.

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Purpose of Activity

To provide information on current recommendations for treating myeloma, including the use of three recently-approved drugs.

Learning Objectives

After completing this continuing education activity you will be able to:

Incorporate into community practice three new drugs for the treatment of myeloma.

Price: $10.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Test Code: OTN0116
Published: Jan 2016
Expires: 1/1/2026
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Mark L. Fuerst
Categories: Cancer , Drug Therapy , Oncology
Specialties: Oncology